Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Finding Study of Poziotinib in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT04402008 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT04402008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04402008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Finding Study of Poziotinib in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
June 23, 2020
Completion date
February 15, 2023
Enrollment
42 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc